Patients with intermediate-to-high-risk localized prostate cancer report similar long-term bowel and urinary symptoms and sexual function whether treated with ultra-hypofractionated radiotherapy or conventional radiotherapy, phase 3 study data show.
The beneficial survival outcomes and low toxicity associated with stereotactic ablative body radiotherapy in patients with extracranial oligometastases persist in the real-world setting.
The results of a meta-analysis point to a link between PARP inhibitor use and a small increase in the risk for developing myelodysplastic syndrome and acute myeloid leukemia.
US researchers report that men with clinically localized, high-risk prostate cancer are no more likely to experience adverse pathologic outcomes if radical prostatectomy is delayed for up to 6 months rather than occurring within 31–60 days of diagnosis.
The number of people initiating systemic cancer therapies fell substantially at the start of the COVID-19 pandemic but then recovered rapidly with the implementation of new treatment guidance, UK study data show.
Treatment with androgen receptor inhibitors is associated with an increased risk for falls and fractures in men with prostate cancer, show findings from a meta-analysis.
Vitamin D supplementation is associated with a reduced risk for metastatic or fatal cancer, but the benefit appears to be largely restricted to people with normal BMI, shows an analysis of VITAL study data.
Stereotactic ablative radiotherapy is associated with “clinically acceptable” rates of toxicity, local control, progression-free survival, and overall survival in people with oligometastatic cancer, meta-analysis data suggest.
Platinum-based chemotherapy is active in patients with advanced castration-resistant prostate cancer and DNA repair gene alterations, shows a chart review.
African–American men with low-risk prostate cancer are more likely to experience disease progression while under active surveillance, and subsequently receive definitive treatment, than their non-Hispanic White counterparts, US study data show.
Data from the phase 3 RADICALS-RT, RAVES, and GETUG-AFU 17 trials and the ARTISTIC meta-analysis suggest that observation with early salvage radiotherapy should be the standard of care for men undergoing radical prostatectomy for localized or locally advanced prostate cancer.
Dual pathway inhibition with the AKT inhibitor ipatasertib plus the androgen receptor inhibitor abiraterone may benefit certain patients with treatment-naïve, metastatic castration-resistant prostate cancer, phase 3 IPATential150 trial data suggest.
Men with metastatic castration-resistant prostate cancer who receive ipilimumab after radiotherapy to bone metastases have a significantly better long-term survival rate than those who receive placebo, study findings indicate.
Phase 2 TRITON2 study data suggest that men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 mutation may benefit from treatment with the PARP inhibitor rucaparib.
Starting radiotherapy up to 6 months after androgen deprivation therapy may be feasible for men with intermediate- and high-risk localized prostate cancer, say US researchers who found that overall survival was comparable regardless of the timing of radiotherapy initiation.
The use of chemohormonal therapy before radical prostatectomy does not significantly improve 3-year biochemical recurrence-free survival in men with localized, high-risk prostate cancer, phase 3 trial findings suggest.